Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients
Tesa M. Severson, Yanyun Zhu, Stefan Prekovic, Karianne Schuurman, Holly M. Nguyen, Lisha G. Brown, Sini Hakkola, Yongsoo Kim, Jeroen Kneppers, Simon Linder, Suzan Stelloo, Cor Lieftink, Michiel van der Heijden, Matti Nykter, Vincent van der Noort, Joyce Sanders, Ben Morris, Guido Jenster, Geert JLH van Leenders, Mark Pomerantz, Matthew L. Freedman, Roderick L. Beijersbergen, Alfonso Urbanucci, Lodewyk Wessels, Eva Corey, Wilbert Zwart, Andries M. Bergman
doi: https://doi.org/10.1101/2023.02.24.23286403
Tesa M. Severson
1Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
2Oncode Institute, Utrecht, the Netherlands
3Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Yanyun Zhu
1Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
2Oncode Institute, Utrecht, the Netherlands
Stefan Prekovic
1Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
2Oncode Institute, Utrecht, the Netherlands
Karianne Schuurman
1Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Holly M. Nguyen
4Department of Urology, University of Washington, Seattle, WA, USA
Lisha G. Brown
4Department of Urology, University of Washington, Seattle, WA, USA
Sini Hakkola
5Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland
Yongsoo Kim
1Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
6Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Jeroen Kneppers
1Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
2Oncode Institute, Utrecht, the Netherlands
Simon Linder
1Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
2Oncode Institute, Utrecht, the Netherlands
Suzan Stelloo
1Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
2Oncode Institute, Utrecht, the Netherlands
7Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University, Nijmegen, 6525 GA Nijmegen, the Netherlands
Cor Lieftink
3Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Michiel van der Heijden
3Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands
8Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Matti Nykter
5Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland
Vincent van der Noort
9Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Joyce Sanders
10Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Ben Morris
3Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Guido Jenster
11Department of Urology, Erasmus MC, Rotterdam, the Netherlands
Geert JLH van Leenders
12Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, the Netherlands
Mark Pomerantz
13Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Matthew L. Freedman
13Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
14The Eli and Edythe L. Broad Institute, Cambridge, MA, USA
Roderick L. Beijersbergen
3Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Alfonso Urbanucci
5Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere, Finland
15Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
Lodewyk Wessels
2Oncode Institute, Utrecht, the Netherlands
3Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands
16Department of EEMCS, Delft University of Technology, Delft, the Netherlands
Eva Corey
4Department of Urology, University of Washington, Seattle, WA, USA
Wilbert Zwart
1Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
2Oncode Institute, Utrecht, the Netherlands
17Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
Andries M. Bergman
1Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands
8Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
Article usage
Posted February 24, 2023.
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients
Tesa M. Severson, Yanyun Zhu, Stefan Prekovic, Karianne Schuurman, Holly M. Nguyen, Lisha G. Brown, Sini Hakkola, Yongsoo Kim, Jeroen Kneppers, Simon Linder, Suzan Stelloo, Cor Lieftink, Michiel van der Heijden, Matti Nykter, Vincent van der Noort, Joyce Sanders, Ben Morris, Guido Jenster, Geert JLH van Leenders, Mark Pomerantz, Matthew L. Freedman, Roderick L. Beijersbergen, Alfonso Urbanucci, Lodewyk Wessels, Eva Corey, Wilbert Zwart, Andries M. Bergman
medRxiv 2023.02.24.23286403; doi: https://doi.org/10.1101/2023.02.24.23286403
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients
Tesa M. Severson, Yanyun Zhu, Stefan Prekovic, Karianne Schuurman, Holly M. Nguyen, Lisha G. Brown, Sini Hakkola, Yongsoo Kim, Jeroen Kneppers, Simon Linder, Suzan Stelloo, Cor Lieftink, Michiel van der Heijden, Matti Nykter, Vincent van der Noort, Joyce Sanders, Ben Morris, Guido Jenster, Geert JLH van Leenders, Mark Pomerantz, Matthew L. Freedman, Roderick L. Beijersbergen, Alfonso Urbanucci, Lodewyk Wessels, Eva Corey, Wilbert Zwart, Andries M. Bergman
medRxiv 2023.02.24.23286403; doi: https://doi.org/10.1101/2023.02.24.23286403
Subject Area
Subject Areas
- Addiction Medicine (376)
- Allergy and Immunology (690)
- Anesthesia (185)
- Cardiovascular Medicine (2780)
- Dermatology (237)
- Emergency Medicine (418)
- Epidemiology (12430)
- Forensic Medicine (10)
- Gastroenterology (787)
- Genetic and Genomic Medicine (4297)
- Geriatric Medicine (397)
- Health Economics (705)
- Health Informatics (2776)
- Health Policy (1029)
- Hematology (371)
- HIV/AIDS (882)
- Medical Education (406)
- Medical Ethics (113)
- Nephrology (455)
- Neurology (4072)
- Nursing (218)
- Nutrition (603)
- Oncology (2154)
- Ophthalmology (608)
- Orthopedics (252)
- Otolaryngology (313)
- Pain Medicine (257)
- Palliative Medicine (79)
- Pathology (480)
- Pediatrics (1152)
- Primary Care Research (473)
- Public and Global Health (6677)
- Radiology and Imaging (1457)
- Respiratory Medicine (889)
- Rheumatology (425)
- Sports Medicine (354)
- Surgery (467)
- Toxicology (57)
- Transplantation (194)
- Urology (172)